By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


About Amgen

Amgen, a pioneer in biotechnology, harnesses the power of cellular and molecular biology and medicinal chemistry to discover, develop and deliver innovative human therapeutics. For more than 25 years, Amgen science has generated important medical discoveries, resulting in medicines that have helped millions of patients fight cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.

Scientific innovation is our heritage and our future. With a deep and broad pipeline of potential new therapeutic candidates, and active research programs in oncology, inflammation, metabolic and bone disorders, hematology, nephrology, and neuroscience, we are dedicated to advancing science to help patients. That dedication shows in our interdisciplinary and modality-independent approach to research and development. Amgen scientists first identify a disease target and then select the best modality – protein, small molecule, or antibody – to interact with that target to block the disease process.

To fully realize the promise of biotechnology to dramatically improve people’s lives, we extend science beyond the lab and clinic, into the production plant. Amgen is recognized worldwide for unparalleled expertise in the complex field of biologics manufacturing. We currently produce more than a third of the world’s non-vaccine and non-insulin protein therapeutics, and we adhere to the highest standards of quality and consistency to ensure a reliable supply of vital medicines for the many patients who need them.

Headquartered in Southern California, with offices or subsidiaries in 31 countries, Amgen is traded on the NASDAQ stock exchange under the symbol AMGN. Amgen is committed to our mission to serve patients – a mission that unites our 15,000 staff members around the world. For more information about Amgen, our pioneering science, and our vital medicines, visit

Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 7,300+ Worldwide
Symbol: AMGN


Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax Corp.  Antibody phage display

Company News
Amgen (AMGN) Receives Positive CHMP Opinion For Use Of Repatha (Evolocumab) For The Treatment Of High Cholesterol 5/22/2015 6:07:04 AM
Amgen (AMGN) Beats Sanofi (SAN.PA) to Market with EU Hurdle for Anti-Cholesterol Drug 5/22/2015 6:02:43 AM
Amgen (AMGN), Sanofi (SAN.PA) in Race to Get European Green light for Anti-Cholesterol Drugs 5/20/2015 10:44:10 AM
Amgen (AMGN) Appoints Jonathan P. Graham Senior Vice President, General Counsel And Secretary 5/19/2015 6:33:24 AM
Amgen (AMGN) Announces Voting Results Of Annual Meeting Of Stockholders 5/15/2015 7:00:25 AM
Amgen (AMGN) Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine 5/15/2015 5:53:02 AM
Amgen (AMGN)'s Migraine Drug Meets Goals in Phase II Study 5/15/2015 5:52:16 AM
Amgen (AMGN) Data At ASCO 2015 Highlight Oncology Pipeline And Portfolio 5/14/2015 10:50:33 AM
Amgen (AMGN)'s Breakaway From Cancer Announces Winners Of Its Nationwide Search For Champions In The Fight Against Cancer 5/13/2015 10:35:43 AM
Amgen (AMGN) To Present AMG 334 Data At 17th Congress of the International Headache Society 5/12/2015 10:07:53 AM